News | November 17, 2010

Lunch Symposium to Highlight Medical Simulation Technology

November 17, 2010 – A lunch symposium detailing the evidence for simulation in medical training and other fields will be sponsored by W.L. Gore and Associates at the VEITHsymposium. The EVEResT (European Virtual Reality Endovascular Research Team) lunch symposium will take place Nov. 19 from 12:00 to 1:00 p.m. in the Gramercy A room, second floor.

Companies will demonstrate how new simulation technologies are designed to enhance performance in endovascular procedures.

Rapid advances in technology and a demand for increased patient safety have led to a growing interest in simulation as a training tool for complex procedures. As a result, some of the world’s leading vascular surgeons and radiologists are participating in the event.

It is chaired by Nicholas Cheshire, M.D., professor of vascular surgery, head of circulation sciences and renal medicine, Imperial College Healthcare, Campus St. Mary’s Hospital, London; Mario Lachat, M.D., head of cardiovascular surgery, University Hospital, Zurich, Switzerland; and Isabelle van Herzeele, M.D., Ph.D, consultant at the department of thoracic and vascular surgery at Ghent University Hospital, Belgium and Honorary Fellow at the department of biosurgery and surgical technology NHS Trust, Campus St. Mary's Hospital, London.

The group was founded involving three academic centers and the three specialties (cardiology, radiology, vascular surgery) involved in endovascular treatments of vascular diseases. This collaboration is intended to inspire other academic centers, professional societies and medical device companies to work together and develop a standardized approach for endovascular training and assessment.


Additional Content

News | Cardiovascular Clinical Studies

Nov. 1, 2026 – Abbott has announced the 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular ...

Home November 03, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 27, 2026 — Atrium Therapeutics, developer of RNA therapeutics targeted to the heart, has announced that the first ...

Home October 30, 2026
Home
News | Cardiovascular Clinical Studies

Oct. 1, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the first patient enrollment in the IBE ...

Home October 01, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 31, 2026 — Amgen has announced new findings showing Repatha (evolocumab) reduced the risk of death in high-risk ...

Home September 02, 2026
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2026 — A new study found that nearly 8 out of 10 young adult participants, average age 23 years, had ...

Home August 21, 2026
Home
Subscribe Now